You are here

  • Home
  • Archive
  • Volume 21, Issue 3
  • Cardiac resynchronisation therapy with an implantable cardioverter defibrillator appears to be cost-effective in patients with mild heart failure

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Cost effectiveness study
Cardiac resynchronisation therapy with an implantable cardioverter defibrillator appears to be cost-effective in patients with mild heart failure
  1. Keith Cooper
  1. University of Southampton, Southampton, UK
  1. Correspondence to : Dr Keith Cooper, University of Southampton, SHTAC, Epsilon House, Enterprise Road, Southampton, SO16 7NS, UK; kc{at}soton.ac.uk

https://doi.org/10.1136/ebmed-2015-110319

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Woo CY, Strandberg EJ, Schmiegelow MD, et al. Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure. Ann Intern Med. 2015;163:417–26.OpenUrlCrossRefPubMed

    Context

    Cardiac resynchronisation therapy (CRT) resynchronises heart contractions using biventricular pacing and may be combined with an implantable cardioverter defibrillator (ICD); this combination is referred to as a CRT-defibrillator (CRT-D). Current clinical guidelines recommend the use of a CRT-D in patients with moderate to severe heart failure, reduced systolic function and ventricular conduction delay.1 Recent clinical trials have shown that CRT also improves outcomes in patients with mild heart failure,2 ,3 but the cost-effectiveness in these patients is unclear. Woo et al …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.